TNFRSF17 and neoplasm: Based on preclinical data showing that gamma‐secretase inhibitors are capable of increasing BCMA expression on the tumor cell surface and concomitantly reducing soluble BCMA levels, which resulted in enhanced activity of BCMA‐targeting BsAbs [78], BCMA‐targeting BsAbs are also evaluated in combination with gamma‐secretase inhibitors in clinical trials.